What does a CMV (cytomegalovirus) IgM (immunoglobulin M) result indicate and how should it be interpreted and managed?

CMV IgM Interpretation and Management

A positive CMV IgM result is highly unreliable as a standalone test and should never be used alone to diagnose acute CMV infection—you must obtain CMV IgG avidity testing to determine if this represents true primary infection, as most isolated IgM-positive results are false positives or reflect non-recent infection. 1

Understanding CMV IgM Test Limitations

CMV IgM testing suffers from severe performance problems that make interpretation treacherous:

• Poor specificity: IgM assays show marked variability across platforms, with only fair-to-moderate agreement (κ = 0.34-0.58) 1
• High false-positive rates: Abbott and NovaLisa platforms show IgM seropositivity rates of 18-19%, while the actual recent infection rate is only 5.5% 1
• Cross-reactivity: Acute EBV infection commonly causes false-positive CMV IgM results 2
• Low sensitivity: In congenital CMV, IgM sensitivity is only 40.7%, missing 51.2% of symptomatic and 77.9% of asymptomatic cases 3
• Can be absent in early primary infection: 2.6% of confirmed early primary infections show negative or equivocal IgM, including 1.0% with IgG levels mimicking past immunity 4

Diagnostic Algorithm for Positive CMV IgM

When you encounter a positive CMV IgM, follow this structured approach:

Step 1: Obtain CMV IgG and IgG Avidity Testing Immediately

• If IgG negative: Likely very early primary infection or false-positive IgM. Repeat testing in 2-3 weeks to look for IgG seroconversion
• If IgG positive with LOW avidity (<30%): Confirms primary infection within past 3-4 months 4
• If IgG positive with HIGH avidity: IgM is false-positive or represents non-recent infection; primary infection occurred >3-4 months ago 5, 1

Step 2: Rule Out EBV Co-infection

• Test for EBV serology (VCA-IgM, VCA-IgG, EBNA) in all CMV IgM-positive patients 5, 2
• Dual CMV/EBV IgM positivity is common and usually indicates EBV as the true pathogen with false-positive CMV IgM 5

Step 3: Consider CMV DNA (PCR) Testing in Blood

• Obtain CMV DNA PCR if clinical suspicion is high (fever, hepatosplenomegaly, elevated liver enzymes, lymphocytosis) 5
• Positive CMV DNA supports active infection but doesn't distinguish primary from reactivation
• Negative CMV DNA strongly argues against clinically significant active infection

Clinical Context Matters

In Immunocompetent Adults

Most isolated CMV IgM-positive results in hospitalized immunocompetent adults do NOT represent clinically significant CMV infection 5. Among 13 hospitalized adults with positive CMV IgM:

• 12/13 also had CMV IgG (suggesting past infection, not primary)
• Only 1 patient received proper avidity testing to confirm primary infection
• Clinical uncertainty was common even with similar presentations

In Pregnancy

For pregnant women, the stakes are higher:

• Primary infection in early pregnancy carries highest fetal risk 6
• IgM can be negative in 1.4% of infections within the first month and 2.1% between 1-2 months after infection onset 4
• Always obtain IgG avidity testing when CMV IgM is positive or when IgG levels are very low (<28 U/mL on LIAISON platform) 4
• Consider repeat serology in 2-3 weeks if IgG is low-positive, as this may represent very early seroconversion 4

In Immunocompromised Patients

For allogeneic HCT, CAR T-cell, or bispecific antibody recipients:

• Serology (IgM/IgG) is NOT useful for monitoring reactivation 7
• CMV DNA PCR monitoring is the standard for CMV-seropositive patients 7
• Testing should be done before lymphodepletion and monitored 2-6 weeks post-infusion in high-risk CAR T-cell recipients 7

Common Pitfalls to Avoid

1. Never diagnose acute CMV based on IgM alone—this leads to misdiagnosis in the majority of cases 1
2. Don't miss EBV—always test for EBV when CMV IgM is positive, as cross-reactivity is common 2
3. Don't assume IgG-positive + IgM-positive = recent infection—this pattern usually represents false-positive IgM in someone with past CMV exposure 1
4. Don't rely on IgM in immunocompromised patients—use CMV DNA PCR instead 7
5. Don't ignore low-reactive IgM values (15-18 U/mL)—these warrant repeat testing or avidity assessment 4

Treatment Decisions

Antiviral treatment should NOT be initiated based on positive IgM alone. Treatment decisions require:

• Confirmed primary infection (low IgG avidity) OR
• Positive CMV DNA with high/rising viral load AND
• Clinical symptoms consistent with CMV disease 5

In the study of hospitalized adults, only 4 of 6 patients with detectable CMV DNA received treatment, reflecting appropriate clinical judgment that not all CMV DNA positivity requires therapy 5.